The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Why venetoclax is a promising new drug for CLL
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about venetoclax for chronic lymphocytic leukemia (CLL). Venetoclax has recently been approved by the FDA to treat relapsed CLL patients with the 17p deletion. According to Dr Ghia, the drug showed great efficacy in the Phase I and II trials; it was able to achieve minimal residual (MRD) negativity in a large fraction of patients. He also discusses the risk of tumor lysis syndrome associated with venetoclax and how this has been adressed.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
